Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Part of paid clinical trials in ‘Aiea, Hawaii.

Sponsor
Gregg T. Kokame, MD
Study ID
NCT01871376
Phase
PHASE4
Status
Completed

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
25 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Intravitreal aflibercept injection 2.0mg — DRUG
    Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.

Study Details

To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV

Key Dates

Start date
May 31, 2013
Status verified
Nov 2016
Primary completion
Sep 30, 2016
Completion
Sep 30, 2016

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Previously Treated
    Patients that have previously received treatment for polypoidal choroidal vasculopathy. Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm.
  • Active Comparator: Treatment-Naive
    Patients that have not received treatment for polypoidal choroidal vasculopathy. Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm.

Primary Outcome Measure

efficacy of intravitreal aflibercept injection of 2.0mg aflibercept [ Time Frame: 2 Years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Retina Consultants of Hawaii‘AieaHawaii96701-

Find similar trials in ‘Aiea, HI

By research site
Retina Consultants of Hawaii· ‘Aiea, HI

Related Studies